Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- 20186 - Steering Committee - Zaritsky No ClinicalTrials.gov identifier reported
- 2018 Aspire Breast Cancer By Invite Only A Phase II Multiinstitutional Study of Concurrent Radiotherapy Palbociclib and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients No ClinicalTrials.gov identifier reported
- 2018 Aspire Breast Cancer By Invite Only Evaluation of Talazoparib A Parp Inhibitor for Patients With Somatic Brca Mutant Metastatic Breast Cancer in A Genotyping Based Clinical Trial No ClinicalTrials.gov identifier reported
- 2018 Aspire Breast Cancer By Invite Only Evaluation of Talazoparib A Parp Inhibitor for Patients With Somatic Brca Mutant Metastatic Breast Cancer in A Genotyping Based Clinical Trial No ClinicalTrials.gov identifier reported
- 2018 Aspire Breast Cancer By Invite Only Phase 2 Trial With Safety Runin of Gedatolisib Plus Talazoparib in Advanced Triple Negative Or Brca1 Or 2 Positive Her2 Negative Breast Cancers No ClinicalTrials.gov identifier reported
- 2018 Aspire Breast Cancer By Invite Only Phase 2 Trial With Safety Runin of Gedatolisib Plus Talazoparib in Advanced Triple Negative Or Brca1 Or 2 Positive Her2 Negative Breast Cancers No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology A Single Arm Prospective Clinical Study Using Novel Wearable Sensors to Assess the Improvement of Nocturnal Scratch Behavior and Sleep Quality in Children With Mildtomoderate Atopic Dermatitis Treated With Topical Crisaborole No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology Research Awards Determing the Impact of Crisaborole and Tacrolimus 003 on Patientreported Outcomes and Caregiver Burden in Children With Atopic Dermatitis No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology Research Awards Determing the Impact of Crisaborole and Tacrolimus 003 on Patientreported Outcomes and Caregiver Burden in Children With Atopic Dermatitis No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology Research Awards Improvement of Short Term Outcome of Atopic Dermatitis Using Combination Treatment of Crisaborole and A Concomitant Topical Corticosteroid Over A 8 Week Period No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology Research Awards Improvement of Short Term Outcome of Atopic Dermatitis Using Combination Treatment of Crisaborole and A Concomitant Topical Corticosteroid Over A 8 Week Period No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology Research Awards Jakstat Signaling in Cutaneous Sarcoidosis An Opportunity for Pathogenesis Directed Therapy No ClinicalTrials.gov identifier reported
- 2018 Aspire Dermatology Research Awards Jakstat Signaling in Cutaneous Sarcoidosis An Opportunity for Pathogenesis Directed Therapy No ClinicalTrials.gov identifier reported
- 2018 Aspire US Inflammatory Bowel Disease Automated Endoscopic Mucosal Disease Activity Scoring for Ulcerative Colitis No ClinicalTrials.gov identifier reported
- 2018-Fc-049 No ClinicalTrials.gov identifier reported
- 2018 Global Aspire TTR Amyloidosis Automatic Diagnosis of Transthyretin Amyloidosis Using Texture and Deep Learning Methods With Echocardiography No ClinicalTrials.gov identifier reported
- 2018 Global Aspire TTR Amyloidosis Trends in Hospital Admissions in Patients With Amyloidosis No ClinicalTrials.gov identifier reported
- 2018: Sra No.20181713 No ClinicalTrials.gov identifier reported
- 2018 US Aspire Attr Cardiomyopathy Establishing Gut Microbiome Signatures to Screen Populations for Attrwtcmp No ClinicalTrials.gov identifier reported
- 2018 US Aspire Endocrinology Prospective Determinants of Longterm Acromegaly Outcomes No ClinicalTrials.gov identifier reported
- 20190136 - Container. No ClinicalTrials.gov identifier reported
- 2019-03 Tidal study No ClinicalTrials.gov identifier reported
- 2019-177 Stemi-Dtu No ClinicalTrials.gov identifier reported
- 2019-3798 Kircik No ClinicalTrials.gov identifier reported
- 2019-4413 Kaminer No ClinicalTrials.gov identifier reported
- 2019-4484 Bajaj No ClinicalTrials.gov identifier reported
- 2019-4517 Goldman No ClinicalTrials.gov identifier reported
- 2019-4535 Liu No ClinicalTrials.gov identifier reported
- 2019-4565 Fabi No ClinicalTrials.gov identifier reported
- 2019-4565- Fabi No ClinicalTrials.gov identifier reported
- 2019-4723 Bagel No ClinicalTrials.gov identifier reported
- 2019-4723-Bagel No ClinicalTrials.gov identifier reported
- 2019-4723 - Bagel No ClinicalTrials.gov identifier reported
- 2019-4723- Bagel No ClinicalTrials.gov identifier reported
- 2019-4816 Bowes No ClinicalTrials.gov identifier reported
- 2019-4816-Bowes No ClinicalTrials.gov identifier reported
- 2019-4816- Bowes No ClinicalTrials.gov identifier reported
- 2019-4898 Gottlieb No ClinicalTrials.gov identifier reported
- 2019-4917 Laquer No ClinicalTrials.gov identifier reported
- 2019-5041 - Lebwohl No ClinicalTrials.gov identifier reported
- 20196 - Protocol Amendment No ClinicalTrials.gov identifier reported
- 2019 Blood Testing Screening Blood Transfusion 2019 with Vitalant No ClinicalTrials.gov identifier reported
- 2019 Cleveland Clinic Vyndaqel Preceptorship Program No ClinicalTrials.gov identifier reported
- 2019-Esr-00133 No ClinicalTrials.gov identifier reported
- 2019 Global Dev AACR Fellowship agreement CORE No ClinicalTrials.gov identifier reported
- 2019nCoV-301 A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults younger or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to under 18 Years) at Risk for SARS-CoV-2 No ClinicalTrials.gov identifier reported
- 2019nCoV-307 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults No ClinicalTrials.gov identifier reported
- 2019nCoV-311 Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines No ClinicalTrials.gov identifier reported
- 2019nCoV-503 Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to less than 12 Years No ClinicalTrials.gov identifier reported
- 2019 Pfizer Cambridge Laboratory Biosafety Permit No ClinicalTrials.gov identifier reported